Recent News

• 12.03.2025 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.02.2025 - Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
• 11.26.2025 - Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
• 11.11.2025 - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
• 11.06.2025 - Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
• 11.05.2025 - Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
• 11.04.2025 - Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
• 10.30.2025 - Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
• 10.28.2025 - Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee
• 10.27.2025 - Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Recent Filings

• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - 144 Report of proposed sale of securities
• 11.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities